Tumor Cell Associated Hyaluronan-CD44 Signaling Promotes Pro-Tumor Inflammation in Breast Cancer.

TitleTumor Cell Associated Hyaluronan-CD44 Signaling Promotes Pro-Tumor Inflammation in Breast Cancer.
Publication TypeJournal Article
Year of Publication2020
AuthorsWitschen PM, Chaffee TS, Brady NJ, Huggins DN, Knutson TP, LaRue RS, Munro SA, Tiegs L, McCarthy JB, Nelson AC, Schwertfeger KL
JournalCancers (Basel)
Volume12
Issue5
Date Published2020 May 22
ISSN2072-6694
Abstract

Cancer has been conceptualized as a chronic wound with a predominance of tumor promoting inflammation. Given the accumulating evidence that the microenvironment supports tumor growth, we investigated hyaluronan (HA)-CD44 interactions within breast cancer cells, to determine whether this axis directly impacts the formation of an inflammatory microenvironment. Our results demonstrate that breast cancer cells synthesize and fragment HA and express CD44 on the cell surface. Using RNA sequencing approaches, we found that loss of CD44 in breast cancer cells altered the expression of cytokine-related genes. Specifically, we found that production of the chemokine CCL2 by breast cancer cells was significantly decreased after depletion of either CD44 or HA. In vivo, we found that CD44 deletion in breast cancer cells resulted in a delay in tumor formation and localized progression. This finding was accompanied by a decrease in infiltrating CD206+ macrophages, which are typically associated with tumor promoting functions. Importantly, our laboratory results were supported by human breast cancer patient data, where increased expression was significantly associated with a tumor promoting inflammatory gene signature. Because high levels of HA deposition within many tumor types yields a poorer prognosis, our results emphasize that HA-CD44 interactions potentially have broad implications across multiple cancers.

DOI10.3390/cancers12051325
Alternate JournalCancers (Basel)
PubMed ID32455980
PubMed Central IDPMC7281239
Grant List132574-CSDG-18-139-01-CSM / / American Cancer Society /
P30 CA077598 / CA / NCI NIH HHS / United States
T32 fellowship, OD010993 / NH / NIH HHS / United States
R01CA235385 / NH / NIH HHS / United States
R01 HD095858 / HD / NICHD NIH HHS / United States
R01HD095858 / NH / NIH HHS / United States
R01 CA215052 / CA / NCI NIH HHS / United States
P30-CA077598 / / Masonic Cancer Center, University of Minnesota /
Related Faculty: 
Nicholas Brady, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700